Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ORCHID: Dolutegravir PK in HIV/TB Co-infected Children
NCT04746547Phase 4Recruiting
- Sponsor
- University of KwaZulu-Natal
- Start
- Aug 2021
- Primary completion
- Jul 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of dolutegravir in human immunodeficiency virus infection (HIV), sponsored by University of KwaZulu-Natal. Primary endpoints: Pharmacokinetics (Ctrough) of DTG at 48 weeks, Pharmacokinetics (Cmax) of DTG at 48 weeks and 1 more. Started Aug 2021; status: recruiting.
02
Drugs
dolutegravir
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT04746547.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04746547.